All Stories

  1. Hormonal Dependence and Cancer in Systemic Lupus Erythematosus
  2. Eficacia y seguridad de rituximab en neuropatía vasculítica: revisión sistemática
  3. Impact of Comorbidity on Physical Function in Patients with Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics. Results from the CAR diovascular in rheu MA tology ( ...
  4. Bacteremia in systemic lupus erythematosus patients from RELESSER: risk factors, clinical and microbiological characteristics and outcomes
  5. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study
  6. Patrones de tratamiento biológico en pacientes con enfermedades articulares inflamatorias. Estudio retrospectivo de 4 años de seguimiento
  7. Análisis de la efectividad, seguridad y optimización de tocilizumab en una cohorte de pacientes con artritis reumatoide en práctica clínica
  8. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis
  9. Meta-analysis of Immunochip data of four autoimmune diseases reveals novel single-disease and cross-phenotype associations
  10. Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort
  11. Recomendaciones de experto sobre el bloqueo de la interleucina 6 en pacientes con artritis reumatoide
  12. Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus
  13. Expert recommendations on the psychological needs of patients with rheumatoid arthritis
  14. Cross-phenotype analysis of Immunochip data identifiesKDM4Cas a relevantlocusfor the development of systemic vasculitis
  15. Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
  16. Genetic variation associated with cardiovascular risk in autoimmune diseases
  17. An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis
  18. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
  19. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study
  20. Genome-wide pathway analysis identifies VEGF pathway association with oral ulceration in systemic lupus erythematosus
  21. Cardiovascular disease in immune-mediated inflammatory diseases
  22. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
  23. Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project
  24. Management of cardiovascular risk in systemic lupus erythematosus: a systematic review
  25. Erratum: Corrigendum: Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy
  26. Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy
  27. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials
  28. Incidence, associated factors and clinical impact of severe infections in a large multicentric cohort of patients with Systemic Lupus Erythematosus
  29. Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study
  30. Documento de Recomendaciones de la Sociedad Española de Reumatología para el manejo clínico del paciente con artritis reumatoide que no puede utilizar metotrexato
  31. Systemic lupus erythematosus in Spanish males: a study of the Spanish Rheumatology Society Lupus Registry (RELESSER) cohort
  32. A functional variant of TLR10 modifies the activity of NFkB and may help predict a worse prognosis in patients with rheumatoid arthritis
  33. Urine metabolome profiling of immune-mediated inflammatory diseases
  34. Estándares de calidad asistencial para las consultas externas de reumatología. El proyecto EXTRELLA
  35. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies
  36. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period o...
  37. Evaluation of the impact of nursing clinics in the rheumatology services
  38. Identification ofIRX1as a Risk Locus for Rheumatoid Factor Positivity in Rheumatoid Arthritis in a Genome-Wide Association Study
  39. Eficiencia de diferentes dosis de rituximab en la artritis reumatoide
  40. Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry
  41. A genome-wide association study identifiesSLC8A3as a susceptibility locus for ACPA-positive rheumatoid arthritis
  42. Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER)
  43. Insulin resistance and levels of adipokines in patients with untreated early rheumatoid arthritis
  44. Influence ofTYK2in systemic sclerosis susceptibility: a newlocusin the IL-12 pathway
  45. Actualización 2014 del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide
  46. Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review
  47. Cardiovascular Events in Systemic Lupus Erythematosus
  48. Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: Baseline data of the CARMA Project
  49. A deletion atADAMTS9-MAGI1locus is associated with psoriatic arthritis risk
  50. Eficacia y seguridad de golimumab añadido a fármacos antirreumáticos modificadores de la enfermedad en artritis reumatoide. Resultados del estudio GO-MORE en España
  51. A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis
  52. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis
  53. Variation at FCGR2A and Functionally Related Genes Is Associated with the Response to Anti-TNF Therapy in Rheumatoid Arthritis
  54. A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility
  55. Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study
  56. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors
  57. Comprehensive Description of Clinical Characteristics of a Large Systemic Lupus Erythematosus Cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) With Emphasis on Complete Versus Incomplete Lupus Differences
  58. Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus
  59. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review
  60. Tofacitinib versus Methotrexate in Rheumatoid Arthritis
  61. The effects of rituximab on the lipid profile of patients with active systemic lupus erythematosus: results from a nationwide cohort in Spain (LESIMAB)
  62. Tocilizumab en pacientes con artritis reumatoide activa y respuesta inadecuada a fármacos antirreumáticos modificadores de la enfermedad o antagonistas del factor de necrosis tumoral: subanálisis de los datos españoles de un estudio abierto cercano a l...
  63. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis
  64. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
  65. Lack of validation of genetic variants associated with anti–tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis
  66. A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility
  67. Immunochip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis
  68. Incidence of Cancer in a Cohort of Spanish Patients With Systemic Lupus Erythematosus
  69. Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico
  70. A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci
  71. GWAS replication study confirms the association of PDE3A–SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis
  72. Reducing the Need for Central Dual-Energy X-Ray Absorptiometry in Postmenopausal Women: Efficacy of a Clinical Algorithm Including Peripheral Densitometry
  73. Quality-of-care standards for early arthritis clinics
  74. The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis
  75. Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: A case control study
  76. Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia
  77. Implication ofIL-2/IL-21region in systemic sclerosis genetic susceptibility
  78. Influence of the IL6 Gene in Susceptibility to Systemic Sclerosis
  79. Survival of Lupus Nephritis Patients After Renal Transplantation In Malaga
  80. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes
  81. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study
  82. No evidence of association between functional polymorphisms located within IL6R and IL6ST genes and systemic sclerosis
  83. Evaluation of a Shared Autoimmune Disease-associated Polymorphism of TRAF6 in Systemic Sclerosis and Giant Cell Arteritis
  84. Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up
  85. Effectiveness of a clinical practice intervention in early rheumatoid arthritis
  86. Systemic Lupus Erythematosus: Genomics, Mechanisms, and Therapies
  87. Clinicopathologic correlations of renal microthrombosis and inflammatory markers in proliferative lupus nephritis
  88. Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis
  89. A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis
  90. A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators
  91. A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations
  92. Tendencia anual de las artroplastias de rodilla y cadera en artritis reumatoide entre 1998-2007
  93. The autoimmune disease-associated IL2RA locus is involved in the clinical manifestations of systemic sclerosis
  94. Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population
  95. Erratum: Corrigendum: Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus
  96. Consenso de uso de rituximab en artritis reumatoide. Un documento con recomendaciones basadas en la evidencia
  97. A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort
  98. Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis
  99. Systemic Diseases: From Amyloidosis to CryoglobulinemiaHereditary fibrinogen A α-chain amyloidosis: Phenotypic characterization of a systemic disease and the role of liver transplantation. Blood 115: 2998–3007, 2010Long-term TNF-α blockade in patients ...
  100. Experiencia con rituximab en el tratamiento de pacientes con lupus. La base de datos LESIMAB
  101. Long-term TNF-α Blockade in Patients with Amyloid A Amyloidosis Complicating Rheumatic Diseases
  102. BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians
  103. Amiloidosis
  104. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients
  105. The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B
  106. The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry
  107. Anti-Cofactor Autoantibodies in Systemic Lupus Erythematosus: Prevalence, Clinical and HLA Class II Associations
  108. Implementación y características de la población del estudio ArtRoCad, una aproximación al consumo de recursos y repercusión socioeconómica de la artrosis de rodilla y cadera en atención primaria
  109. Registrolesaf. Características de los pacientes con lupus eritematoso sistémico y síndrome antifosfolipídico registrados por usuarios médicos especialistas en reumatología y medicina interna
  110. Systemic lupus erythematosus in Europe at the change of the millennium: Lessons from the “Euro-Lupus Project”
  111. Errata
  112. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists
  113. Systemic lupus erythematosus in southern Spain: a comparative clinical and genetic study between Caucasian and Gypsy patients
  114. Manifestaciones clínicas y alteraciones inmunológicas en pacientes con síndrome antifosfolipídico. Presentación de 112 casos
  115. Morbidity and Mortality in Systemic Lupus Erythematosus During a 10-Year Period
  116. HLA-DPB1 alleles association of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus
  117. HLA Class II DNA Typing in a Large Series of European Patients with Systemic Lupus Erythematosus
  118. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
  119. Morbidity and Mortality in Systemic Lupus Erythematosus During a 5-Year Period: A Multicenter Prospective Study of 1,000 Patients
  120. Localized rheumatoid vasculitis presenting as acute alithiasic cholecystitis
  121. Psoas abscess secondary to brucellosis